These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30606734)

  • 1. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
    Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
    Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome.
    Lleó A; Carmona-Iragui M; Videla L; Fernández S; Benejam B; Pegueroles J; Barroeta I; Altuna M; Valldeneu S; Xiao MF; Xu D; Núñez-Llaves R; Querol-Vilaseca M; Sirisi S; Bejanin A; Iulita MF; Clarimón J; Blesa R; Worley P; Alcolea D; Fortea J; Belbin O
    Alzheimers Res Ther; 2021 Jun; 13(1):119. PubMed ID: 34183050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
    Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum.
    Goossens J; Cervantes González A; Dewit N; Lidón L; Fortea J; Alcolea D; Lleó A; Belbin O; Vanmechelen E
    Alzheimers Res Ther; 2023 Oct; 15(1):186. PubMed ID: 37898760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
    Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.
    Camporesi E; Nilsson J; Vrillon A; Cognat E; Hourregue C; Zetterberg H; Blennow K; Becker B; Brinkmalm A; Paquet C; Brinkmalm G
    EBioMedicine; 2022 Jan; 75():103793. PubMed ID: 34990894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
    Visser PJ; Reus LM; Gobom J; Jansen I; Dicks E; van der Lee SJ; Tsolaki M; Verhey FRJ; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Molinuevo JL; Engelborghs S; Freund-Levi Y; Froelich L; Sleegers K; Dobricic V; Lovestone S; Streffer J; Vos SJB; Bos I; ; Smit AB; Blennow K; Scheltens P; Teunissen CE; Bertram L; Zetterberg H; Tijms BM
    Mol Neurodegener; 2022 Mar; 17(1):27. PubMed ID: 35346299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
    Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
    Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
    Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
    Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
    Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
    Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.
    Wildsmith KR; Schauer SP; Smith AM; Arnott D; Zhu Y; Haznedar J; Kaur S; Mathews WR; Honigberg LA
    Mol Neurodegener; 2014 Jun; 9():22. PubMed ID: 24902845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H; Lyu D; Jia J;
    J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
    Hendrickson RC; Lee AY; Song Q; Liaw A; Wiener M; Paweletz CP; Seeburger JL; Li J; Meng F; Deyanova EG; Mazur MT; Settlage RE; Zhao X; Southwick K; Du Y; Holder D; Sachs JR; Laterza OF; Dallob A; Chappell DL; Snyder K; Modur V; King E; Joachim C; Bondarenko AY; Shearman M; Soper KA; Smith AD; Potter WZ; Koblan KS; Sachs AB; Yates NA
    PLoS One; 2015; 10(8):e0135365. PubMed ID: 26270474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum.
    Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D
    Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
    Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.
    Jahn H; Wittke S; Zürbig P; Raedler TJ; Arlt S; Kellmann M; Mullen W; Eichenlaub M; Mischak H; Wiedemann K
    PLoS One; 2011; 6(10):e26540. PubMed ID: 22046305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.
    Höglund K; Schussler N; Kvartsberg H; Smailovic U; Brinkmalm G; Liman V; Becker B; Zetterberg H; Cedazo-Minguez A; Janelidze S; Lefevre IA; Eyquem S; Hansson O; Blennow K
    Neurobiol Dis; 2020 Feb; 134():104645. PubMed ID: 31669672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.